Novartis (NVS) Stock Forecast & Price Target

$110.16 -0.93 (-0.84%)

As of 03:45 PM Eastern

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 10 Analyst Ratings

Sell
3

Hold
6

Buy
1

Based on 10 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 10 analysts, 3 have given a sell rating, 6 have given a hold rating, and 1 has given a buy rating for NVS.

Consensus Price Target

$123.38
12.00% Upside

According to the 10 analysts' twelve-month price targets for Novartis, the average price target is $123.38. The highest price target for NVS is $130.00, while the lowest price target for NVS is $120.00. The average price target represents a forecasted upside of 12.00% from the current price of $110.16.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

NVS Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)	3 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$123.38	$123.38	$121.50	$104.33
Forecasted Upside	12.00% Upside	12.76% Upside	23.54% Upside	8.99% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

Remove Ads

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.80	2.82	2.54
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	11.01% Upside	21,088.48% Upside	16.92% Upside
News Sentiment Rating	Positive News See Recent NVS News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/13/2025	UBS Group 4 of 5 stars	Matthew Weston Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/12/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Underweight
2/4/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Upgrade	Hold ➝ Buy
2/3/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underweight ➝ Underweight
12/4/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Reduce
11/19/2024	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$118.00 ➝ $120.00	+8.53%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:58 PM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 23, 2025. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Novartis AG's stock is currently trading at $113.35, reflecting a strong market capitalization of $231.68 billion, which indicates a solid position in the pharmaceutical industry.
The company has received a recent upgrade from StockNews.com, moving from a "buy" rating to a "strong-buy" rating, suggesting positive sentiment among analysts regarding its future performance.
Novartis AG has a relatively low debt-to-equity ratio of 0.48, indicating a strong balance sheet and lower financial risk, which can be attractive to investors looking for stability.
Recent institutional investments, including new positions from various hedge funds, demonstrate growing confidence in Novartis AG's potential, with 13.12% of the stock owned by institutional investors.
The company has a consistent history of innovation in pharmaceuticals, which can lead to sustained revenue growth and profitability, making it a potentially lucrative investment opportunity.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Despite recent upgrades, several analysts still maintain a "hold" or "underweight" rating on Novartis AG, indicating mixed sentiments about its stock performance.
HSBC recently downgraded Novartis AG from a "hold" to a "reduce" rating, which may suggest concerns about the company's growth prospects in the near term.
The stock has experienced fluctuations, with a 52-week low of $92.35, indicating potential volatility that could deter risk-averse investors.
Competition in the pharmaceutical sector is intense, and Novartis AG may face challenges in maintaining its market share against emerging therapies and generics.
Recent reports indicate that some institutional investors are reducing their stakes in Novartis AG, which could signal a lack of confidence in the company's future performance.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $123.38, with a high forecast of $130.00 and a low forecast of $120.00.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NVS shares.
: According to analysts, Novartis's stock has a predicted upside of 12.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 1 upgrade by analysts.
: Novartis has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Morgan Stanley, and UBS Group in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:NVS) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target